Calliditas Therapeutics (CALT) has released an update.
At the annual general meeting of Calliditas Therapeutics, key resolutions included the adoption of financial statements for 2023, re-election of board members and auditors, and the decision to not distribute dividends for the year. Additionally, the company was authorized to issue new shares, warrants, and/or convertibles up to 20% of the total shares, and to transfer its own shares, to increase financial and operational flexibility. The meeting also approved new long-term incentive programs for board members and key personnel, and updated remuneration guidelines for group management.
For further insights into CALT stock, check out TipRanks’ Stock Analysis page.
